Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment
LONDON, July 26, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that …